Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the fi

First Canadian update in nearly 20 years prioritizes improvements in health and quality of life over weight loss outcomesEDMONTON, Alberta, April 14, 2025 (GLOBE NEWSWIRE) -- Healthcare providers and families have a new roadmap to support collaborative, fully-informed, evidence-based care for children and adolescents living with obesity, thanks to a new clinical practice guideline published today in the Canadian Medical Association Journal. The guideline was developed by Obesity Canada throug

GUANGZHOU, China, April 13, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leading Internet healthcare solution provider, participated in the "AI Empowers Biopharma" exchange panel hosted by the Guangzhou Development District Talent Education Group on April 3, 2025, joining 28 enterprises to explore cutting-edge applications of AI healthcare. Guo Zhi, Senior Vice President of Technology of Fangzhou, shared during the panel: "At Fangzhou, we've systematically addre

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). “The appr

iStock, AndreyPopov Future Pak—whose acquisition offer was rejected by Vanda Pharmaceuticals last summer—is offering to buy Theratechnologies for an unsolicited $255 million. The Canadian biotech is under an exclusivity agreement with another yet-to-be-disclosed potential purchaser. Theratechnologies has been in talks with an undisclosed company that is looking to acquire the biotech, the Canadian company revealed over the weekend. This news comes after pharmaceutical packaging manufacturer F

In recent years, the pharmaceutical landscape for rare diseases has witnessed a remarkable evolution. Rare diseases, often referred to as orphan diseases, affect small patient populations, yet collectively they impact more than 300 million people worldwide and account for a significant portion of the global clinical development pipeline.This blog delves into the rise of rare disease drug approvals and the critical importance of regulatory guidance in shaping the future of rare disease drug devel

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald April 14, 2025 WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: St

Taylor Tieden for BioSpace Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi. The FDA has three big decisions slated for the back half of April, two of which are for Regeneron’s blockbuster franchises. Read below for more. Regeneron, Sanofi Eye Another Expansion for Dupixent Following an initial rejection in October 2023, Regeneron and Sanofi are again trying to expand their anti-inf

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug Administration (FDA) to treat patients with hepatocellular carcinoma (HCC), the most common type of liver cancer. Opdivo (nivolumab) plus Yervoy (ipilimumab) is now authorised by the regulator as a first-line treatment for adults with unresectable or advanced cases of the disease. Approximately 42,240 people in the US are expected to be diagnosed with liver cancer this year.

Genetically engineered chimeric antigen receptor immune cell with implanted mrna gene strand - 3d illustration Christoph Burgstedt/Getty Images At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies. FDA approval for chimeric antigen receptor (CAR) T cell therapy occurred 30 years after the initia